The grant process involves inviting specific scientists to respond to a request for applications (RFA). Once those materials are received they are reviewed by the Medical Advisory Board and the Board of Directors of the Inflammatory Breast Cancer Research Foundation.
Dr. Schneider’s project built on his research identifying potential therapeutic targets in inflammatory breast cancer (IBC) following neoadjuvant chemotherapy.
Dr. Schneider has received two grants from our organization. He continues to be a leader in translational inflammatory breast cancer research and works with an outstanding group of collaborators.
He has a special interest in understanding the molecular underpinnings of inflammatory breast cancer. Dr. Schneider serves as Associate Dean in the Office of Therapeutics Alliances, is Co-director of the Breast Cancer Program and Albert Sabin Professor of Molecular Pathogenesis at NYU School of Medicine.
The focus of the 2015 grant, metastatic triple negative inflammatory breast cancer, is a particularly challenging form of the disease. This is an area of high interest for the Milburn Foundation whose generous support helped fund this work.